
2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES:
REGISTRY ONLY

DESCRIPTION:
Percentage of patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) who are receiving erythropoietin therapy with documentation of iron stores within 60 days prior to initiating erythropoietin therapy

INSTRUCTIONS:
This measure is to be reported a minimum of once per reporting period for all myelodysplastic syndrome (MDS) patients seen during the reporting period, regardless of when erythropoietin therapy is initiated; the quality action being measured is that iron stores were documented for each MDS patient receiving erythropoietin therapy within 60 days of starting erythropoietin therapy, regardless of how far back the erythropoietin therapy initiated. It is anticipated that clinicians who provide services for patients with the diagnosis of myelodysplastic syndromes will submit this measure.

Measure Reporting via Registry:
ICD-10-CM diagnosis codes, CPT codes, CPT Category II and patient demographics are used to identify patients who are included in the measure’s denominator. The listed numerator options are used to report the numerator of the measure.

The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

DENOMINATOR:
All patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) who are receiving erythropoietin therapy

Definition:
Erythropoietin Therapy – Includes the following medications: epoetin and darbepoetin for the purpose of this measure.

Denominator Criteria (Eligible Cases):
Patients aged ≥ 18 years on date of encounter
AND
Diagnosis for MDS (ICD-10-CM): D46.0, D46.1, D46.20, D46.21, D46.22, D46.4, D46.9, D46.A, D46.B, D46.C, D46.Z
AND
Patient encounter during the reporting period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215
AND
Patient receiving erythropoietin therapy: 4090F

NUMERATOR:
Patients with documentation of iron stores within 60 days prior to initiating erythropoietin therapy

Definition:
Documentation of Iron Stores – Includes either: 1) bone marrow examination including iron stain OR 2) serum iron measurement including ferritin, serum iron and total iron-binding capacity (TIBC).

Numerator Options:
Performance Met: Documentation of iron stores prior to initiating erythropoietin therapy (3160F)

OR

System Performance Exclusion: Documentation of system reason(s) for not documenting iron stores prior to initiating erythropoietin therapy (3160F with 3P)

OR

Performance Not Met: Iron stores prior to initiating erythropoietin therapy not documented, reason not otherwise specified (3160F with 8P)

RATIONALE:
To be effective erythropoietin requires that adequate iron stores be present due to iron’s importance in red-blood-cell synthesis. Iron deficiency presents a major limitation to the efficacy of erythropoietin therapy.

CLINICAL RECOMMENDATION STATEMENTS:
The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines:

Anemia related to MDS generally presents as a hypoproducative macrocytic anemia, often associated with suboptimal elevation of serum Epo levels. Iron repletion needs to be verified before instituting Epo or darbepoetin therapy.

(Category 2A Recommendation) (NCCN, 2015)

COPYRIGHT:
These Physician Performance Measures (Measures) are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.

The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the American Medical Association (AMA), [on behalf of the Physician Consortium for Performance Improvement® (PCPI®)] or the American Society of Hematology (ASH). Neither the AMA, ASH, PCPI nor its members shall be responsible for any use of the Measures.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

© 2006-7 American Medical Association and American Society of Hematology. All Rights Reserved. Applicable

FARS/DFARS Restrictions Apply to Government Use.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, ASH, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

2016 Registry Individual Measure Flow

PQRS #68 NQF # 0378: Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

**Start**

**Denominator**

- Patient Age at Date of Service ≥ 18 Years
  - Yes
  - Diagnosis for MDS as Listed in Denominator*
    - Yes
    - Encounter as Listed in Denominator* (1/1/2016 thru 12/31/2016)
      - Yes
      - Receiving Erythropoietin 4090F or equivalent
        - Yes
        - Include in Eligible Population/Denominator (8 patients)
        - No
    - No
    - Not Included in Eligible Population/Denominator
      - Yes
      - Reporting Not Met
        - Quality Data Code or equivalent not reported (1 patient)

**Numerator**

- Documentation of Iron Stores Prior to Initiating Erythropoietin Therapy
  - Yes
  - Reporting Met + Performance Met 3160F or equivalent (4 patients)
    - No
  - Documentation of System Reason(s) for Not Documenting Iron Stores Prior to Initiating Erythropoietin Therapy
    - Yes
    - Reporting Met + Performance Exclusion 3160F-3P or equivalent (1 patient)
    - No
    - Iron Stores Prior to Initiating Erythropoietin Therapy Not Documented, Reason Not Otherwise Specified
      - Yes
      - Reporting Met + Performance Not Met 3160F-6P or equivalent (2 patients)
      - No
      - Reporting Not Met
        - Quality Data Code or equivalent not reported (1 patient)

**SAMPLE CALCULATIONS:**

- Reporting Rate=
  - Performance Met (a=4 patients) × Performance Exclusion (b=1 patient) × Performance Not Met (c=2 patients) = 7 patients = 87.50%
  - Eligible Population / Denominator (d=8 patients)
  - = 8 patients

- Performance Rate=
  - Performance Met (a=4 patients)
  - Reporting Numerator (7 patients) – Performance Exclusion (b=1 patient) = 4 patients = 66.67%
  - Performance Not Met (c=2 patients)
  - Reporting Numerator (7 patients) = 6 patients

*See the posted Measure Specification for specific coding and instructions to report this measure.

NOTE: Reporting Frequency: Patient- process
2016 Registry Individual Measure Flow
PQRS #68 NQF #0378: Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

Please refer to the specific section of the Measure Specification to identify the denominator and numerator information for use in reporting this Individual Measure.

1. Start with Denominator

2. Check Patient Age:
   a. If the Patient Age is greater than or equal to 18 Years of age at Date of Service and equals No during the measurement period, do not include in Eligible Patient Population. Stop Processing.
   b. If the Patient Age is greater than or equal to 18 Years of age at Date of Service and equals Yes during the measurement period, proceed to check Patient Diagnosis.

3. Check Patient Diagnosis:
   a. If Diagnosis for MDS as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Diagnosis for MDS as Listed in the Denominator equals Yes, proceed to check Encounter.

4. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, proceed to check Receiving Erythropoietin.

5. Check Receiving Erythropoietin:
   a. If Receiving Erythropoietin equals No, do not include in Eligible Patient Population. Stop Processing.
   b. Receiving Erythropoietin 4090F or equivalent Yes, include in the Eligible Patient Population.

6. Denominator Population:
   a. Denominator population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 8 patients in the sample calculation.

7. Start Numerator

8. Check Documentation of Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy:
   a. If Documentation of Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy equals Yes, include in Reporting Met and Performance Met.
   b. Reporting Met and Performance Met letter is represented in the Reporting Rate and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 4 patients in Sample Calculation.
c. If Documentation of Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy equals No, proceed to Documentation of System Reason(s) for Not Documenting Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy.

9. Check Documentation of System Reason(s) for Not Documenting Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy:
   a. If Documentation of System Reason(s) for Not Documenting Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy equals Yes, include in Reporting Met and Performance Exclusion.
   b. Reporting Met and Performance Exclusion is represented in the Reporting Rate and Performance Rate in the Sample Calculation listed at the end of this document. Letter b equals 1 patient in the Sample Calculation.
   c. If Documentation of System Reason(s) for Not Documenting Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy equals No, proceed to Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy Not Documented, Reason Not Specified.

10. Check Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy Not Documented, Reason Not Specified:
    a. If Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy Not Documented, Reason Not Specified equals Yes, include in the Reporting Met and Performance Not Met.
    b. Reporting Met and Performance Not Met letter is represented in the Reporting Rate in the Sample Calculation listed at the end of this document. Letter c equals 2 patients in the Sample Calculation.
    c. If Iron Stores within 60 days Prior to Initiating Erythropoietin Therapy Not Documented, Reason Not Specified equals No, proceed to Reporting Not Met.

11. Check Reporting Not Met:
    a. If Reporting Not Met, the Quality Data Code or equivalent was not reported. 1 patient has been subtracted from the reporting numerator in sample calculation.

<table>
<thead>
<tr>
<th>Sample Calculations:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reporting Rate=</strong></td>
</tr>
<tr>
<td>Performance Met (a=4 patients) + Performance Exclusion (b=1 patient) + Performance Not Met (c=2 patients) = 7 patients = 87.50%</td>
</tr>
<tr>
<td>Eligible Population / Denominator (d=8 patients) = 8 patients</td>
</tr>
<tr>
<td><strong>Performance Rate=</strong></td>
</tr>
<tr>
<td>Performance Met (a=4 patients) = 4 patients = 66.67%</td>
</tr>
<tr>
<td>Reporting Numerator (7 patients) – Performance Exclusion (b=1 patient) = 6 patients</td>
</tr>
</tbody>
</table>